15.03.2023 • NewsSumitomoBiopharmacancer

Sumitovant Closes Myovant Purchase

US biopharma Sumitovant – a wholly owned subsidiary of Japan’s Sumitomo Pharma – has closed its purchase of the remaining equity in Myovant Sciences, taking full control of the Swiss clinical-stage biopharma for about $1.7 billion. Myovant will now be delisted from the New York Stock Exchange.

© Getty Images
© Getty Images

“We are excited to have officially completed our acquisition of Myovant and look forward to working together to address unmet needs in women’s health and prostate cancer,” said Sumitovant’s CEO Myrtle Potter. “By combining our unique expertise, platforms and resources, we will be better positioned to drive the growth of Myovant’s products and accelerate the development of our robust combined pipeline.”

Prior to its takeover, Sumitovant was Myovant’s largest shareholder with a 52% stake. It said it had invested about $600 million into the Basel-based pharma over the past several years to support the development of new drugs to treat advanced prostate cancer (Orgovyx), and uterine fibroids and endometriosis (Myfembree).

Last October, Myovant rejected a first offer from Sumitovant, saying it significantly undervalued the company.

Author: Elaine Burridge, Freelance Journalist

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read